Skip to main content

Table 3 Adopters per drug and specialty and time of adoption

From: Adoption of new drugs by physicians: a survival analysis

     Time of adoption
Drug Specialty Number of prescribers Number of adopters (%) Median in months (intercuartile range) Comparison with Family Physicians. Log-rank test
      χ 2 p-value
Cefditoren Otolaryngology 19 11 (58%) 2 (2-5) 6.76 0.01
  Family physicians 232 50 (22%) 4 (3-7)   
  Internal medicine 22 4 (18%) 5 (3-10) 0.44 NS
  Emergencies 65 7 (11%) 9 (5-21) 6.39 0.01
  Pneumology 15 7 (47%) 9 (8-12) 1.14 NS
Duloxetine Psychiatry 36 22 (61%) 2 (2-3) 29.55 < 0.01
  Family physicians 252 160 (63%) 4 (3-6)   
Etoricoxib Rheumatology 6 3 (50%) 2 (1-8) 8.08 < 0.01
  Traumatology 55 21 (38%) 3 (2-15) 1.97 NS
  Family physicians 230 105 (46%) 10 (3-20)   
  Rehabilitation 14 2 (14%) 11 (11-26) 0.51 NS
Ezetimibe Cardiology 16 6 (38%) 2 (1-3) 8.13 < 0.01
  Endocrinology 11 8 (73%) 3 (2-3) 10.95 < 0.01
  Family physicians 258 168 (65%) 5 (3-8)   
Levocetirizine Otolaryngology 19 8 (42%) 1 (1-4) 24.14 < 0.01
  Allergology 10 10 (100%) 4 (2-7) 4.96 0.03
  Emergencies 44 4 (9%) 4 (4-12) 0.73 NS
  Dermatology 15 12 (80%) 9 (2-12) 1.54 NS
  Family physicians 264 141 (53%) 10 (7-13)   
Olmesartan Cardiology 15 3 (20%) 1 (1-2) 17.23 < 0.01
  Internal medicine 21 3 (14%) 2 (2-13) 0.04 NS
  Family physicians 256 154 (60%) 6 (3-9)   
Pregabalin Anesthesiology 8 3 (38%) 2 (2-5) 8.45 < 0.01
  Neurology 17 8 (47%) 3 (2-4) 12.1 < 0.01
  Rheumatology 6 6 (100%) 3 (2-4) 9.83 < 0.01
  Rehabilitation 23 17 (74%) 5 (2-7) 2.94 NS
  Family physicians 275 180 (65%) 6 (4-10)   
  Traumatology 56 17 (30%) 6 (4-9) 0.87 NS
Tiotropium Pneumology 15 14 (93%) 1 (1-2) 49.18 < 0.01
  Internal medicine 30 14 (47%) 2 (2-5) 0.13 NS
  Family physicians 297 207 (70%) 3 (2-4)   
  1. NS: p > 0.05